In addition to the demonstrated efficacy of Haprolid in inhibiting DHX9 and suppressing AKT signaling, evaluating its potential synergy with existing HCC treatments, such as sorafenib, would be an important next step. Here, DHX9 is linked to hepatocellular carcinoma.